Armistice Capital

Adocia is a clinical-stage biotechnology company based in Lyons, France, founded in 2005 and known for its focus on tissue regeneration. The company specializes in developing formulations of approved therapeutic proteins and peptides aimed at treating diabetes and other metabolic diseases. Adocia has created a proprietary technology platform called Biochaperone, which enhances the effectiveness of these therapeutic proteins. Its clinical pipeline includes products such as Biochaperone Lispro, Biochaperone Combo, and Biochaperone Glucagon, while its pre-clinical pipeline features BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Additionally, Adocia holds a patent portfolio that primarily addresses chronic wound healing, insulin therapy, and monoclonal antibodies.

ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

Assembly Biosciences is a clinical-stage biotechnology company focused on two platform programs: hepatitis B virus HBV therapeutics and microbiome-based oral biotherapeutics. The HBV program aims to increase cure rates by developing core protein inhibitors that disrupt multiple steps of the viral lifecycle, with candidates in varying stages of clinical development. The microbiome program uses an integrated platform for disease-targeted strain identification, isolation, characterization, and growth under current good manufacturing practices, along with a patented delivery system called GEMICEL that enables targeted oral delivery of live biologics and conventional therapies to the lower gastrointestinal tract; the lead microbiome program targets Clostridioides difficile infections. The company pursues collaborations to advance these programs, including agreements with Allergan for microbiome GI programs and with Door Pharmaceuticals for HBV core modulators. Founded in 2005 and headquartered in South San Francisco, Assembly Biosciences focuses on therapies for HBV and microbiome-associated diseases.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies that modulate the immune system to treat cancer. Its pipeline includes Ciforadenant, an oral A2A receptor antagonist, CPI-006, an anti-CD73 antibody, CPI-818, an ITK inhibitor, and soquelitinib, an ITK-targeting agent. The company was founded in 2014 and is based in Burlingame, California.

Zura Bio is a clinical-stage company focused on immunology. It develops therapies for autoimmune illnesses using its proprietary assets ZB-168 and torudokimab. ZB-168, an anti-IL7R inhibitor, targets disorders involving IL7 and TSLP pathways. Torudokimab, a human-affinity monoclonal antibody, neutralizes IL33. Both assets are in Phase 2 clinical development.

Protara Therapeutics is a clinical-stage company focused on identifying and advancing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations, while IV choline chloride is an investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease. The company is based in New York, New York.

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. Its lead product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction in diseases like Dementia with Lewy Bodies (DLB) and other related neurological conditions.

Founded in 1937, Greenidge Generation is a power plant based in Dresden, New York. It operates as a vertically integrated cryptocurrency data center, generating revenue through bitcoin mining using application-specific integrated circuit computers.

Tenaya Therapeutics is a preclinical stage biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs a multipronged approach to address the fundamental cellular pathologies associated with cardiac muscle disease. Tenaya Therapeutics advances its product candidates through three primary platforms: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads to cardiac fibroblasts, and a precision medicine platform that offers personalized treatment strategies. Through its research, the company aims to enable physicians to regenerate heart tissue and tackle various forms of cardiomyopathies effectively.

Outlook Therapeutics is a late-stage biopharmaceutical company dedicated to developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently in Phase-III trials for treating wet age-related macular degeneration and other retina diseases.

Aligos Therapeutics is a biopharmaceutical company dedicated to developing innovative therapeutics targeting viral infections and liver diseases. Founded in 2018, the company focuses on chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH), leveraging its expertise in liver disease drug development.

Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy-based treatments for severe and life-threatening rare genetic diseases. Its pipeline includes therapies for Sanfilippo syndrome types A and B, epidermolysis bullosa, Batten disease, cystic fibrosis, and genetic eye disorders.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

Eyenovia, Inc. is a clinical-stage ophthalmic biopharmaceutical company based in New York, specializing in the development of innovative microdose therapeutics through its proprietary piezo-print delivery technology called the Optejet. Founded in 2014, Eyenovia aims to transform the delivery of ophthalmic therapies by providing high-precision, targeted administration of medications, which has the potential to replace traditional eye droppers and enhance safety, tolerability, and patient compliance. The company is advancing several product candidates, including MicroLine for presbyopia, MicroProst for chronic angle closure glaucoma and other conditions, MicroStat for mydriasis, MicroTears for red eye and itch relief, and MicroPine for progressive myopia. Eyenovia focuses on developing treatments for ophthalmic diseases where no FDA-approved therapies currently exist, contributing to its goal of improving patient care in the field of eye health.

Xeris Biopharma is a specialty pharmaceutical company developing ready-to-use, liquid-stable injectables using its proprietary XeriSol and XeriJect formulation technologies. These platforms enable subcutaneous and intramuscular delivery of various drugs, offering advantages such as room temperature stability, reduced injection volume, and ease of use for patients and healthcare practitioners.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Mauna Kea Technologies is a medical device company that develops, manufactures and markets imaging solutions for real-time cellular-level visualization during minimally invasive procedures to improve cancer and other disease diagnosis and treatment. Its flagship Cellvizio platform combines a probe-based endomicroscopy system that provides in vivo cellular images during procedures, enabling clinicians to assess tissue at the microscopic level in real time. The company serves customers globally, with products cleared or approved in the United States and more than 40 countries, and operates across Europe, the Middle East, Africa, the Americas, and Asia. Mauna Kea aims to eliminate uncertainties in diagnosis and treatment by visualizing tissue in vivo during standard procedures.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.

Medigus is a medical device company that develops, produces, and markets minimally invasive endoscopic tools and direct visualization technology worldwide. Founded in 1999 and headquartered in Omer, Israel, it offers the Ultrasonic Surgical Endostapler and a complete endoscopic system for intraluminal treatment of gastroesophageal reflux disease. The system combines a miniature video camera, a surgical stapler, and ultrasonic alignment to enable a true partial anterior fundoplication without open or laparoscopic surgery. Medigus also designs and manufactures endoscopy systems for partners, providing the world’s smallest video cameras, processors, and a range of disposable endoscopes. The company focuses on innovative endoscopic procedures and aims to shift GERD treatment from surgery to endoluminal procedures.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, specializing in the discovery, development, and commercialization of novel orally available small-molecule drugs, particularly allosteric modulators targeting central nervous system (CNS) disorders. The company's leading programs include Dipraglurant, aimed at treating levodopa-induced dyskinesia in Parkinson's disease and dystonia, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB positive allosteric modulator for addiction. Addex Therapeutics emphasizes the advantages of allosteric modulators over traditional non-allosteric molecules, as they may provide improved therapeutic solutions. The company also has a collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for therapeutic use. Founded in 2002, Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd and rebranded in March 2012.